Novel, Fractionated Dosing Formulations for
Optimizing Titration of
Carbidopa/Levodopa
A Practical Roadmap for Improving Patient Satisfaction, Motor Symptoms,
Clinical Outcomes, and ON/OFF Time in Persons with PD
A Practical Roadmap for Improving Patient Satisfaction, Motor Symptoms,
Clinical Outcomes, and ON/OFF Time in Persons with PD
Latest Videos |view all videos
Video
What is the initial starting dose of carbidopa/levodopa, and what is the range of CD/LD formulations currently available for PD? Why does the eventual onset of motor fluctuations and “wearing off” observed over time present opportunities ...
Video
What makes the scored, fractionated formulation of CD/LD different from other tablets and what group of patients should be considered appropriate candidates for treatment with this titratable treatment for PD?
Video
Can you summarize your current treatment algorithm for treating “off time?”
Can you summarize your current treatment algorithm for treating “off time?”
Video
Can you share a person you have managed who has experienced increased “off time” and motor fluctuations with CD/LD who might be an ideal patient for treatment with titratable formulations, including those based on scored, fractionable doses of CD/LD?
Video
What medication compliance factors do you stress with patients who are on CD/LD and what compliance shortfalls—and variable responses to CD/LD—have you witnessed that provide rationale for using the CD/LD fractionable dosing formulation?
Video
Can you provide an example where the foundational approaches/formulations of CD/LD have not been satisfactory due to increasing “off time;” and, how you might deploy the scored CD/LD fractionable dosing formulation to address this clinical challenge?
Video
Despite the plethora of CD/LD formulations available to address the increasing “off time” that accompanies progressive PD, what are the advantages and indications of the newly FDA-approved CD/LD scored, fractionable dosing formulation?
Video
What are the currently available dosing formulations of CD/LD, and what potential advance in PD treatment has been made possible with the availability of a CD/LD fractionable dosing formulation (Dhivy®)?
Video
Can you be specific about the challenges encountered in persons who have been treated with a fixed dose of carbidopa/levodopa (CD/LD) and begin to show signs of therapeutic resistance, manifested by increasing “Off times” and/or suboptimal response?